Taken together, our molecular and cellular results suggest that MPG may be implicated in conferring drug resistance to glioblastomas harboring mutations in either ATRX or p53 or both, which account for around 60% of all glioblastomas. This evidence concerns the gene ATRX and glioblastoma.